- Home
- CSPI vs MGNX Comparison
CSPI vs MGNX Comparison
Compare CSPI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSPI
- MGNX
- Stock Information
- Founded
- CSPI 1968
- MGNX 2000
- Country
- CSPI United States
- MGNX United States
- Employees
- CSPI N/A
- MGNX N/A
- Industry
- CSPI EDP Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CSPI Technology
- MGNX Health Care
- Exchange
- CSPI Nasdaq
- MGNX Nasdaq
- Market Cap
- CSPI 174.4M
- MGNX 151.9M
- IPO Year
- CSPI 1987
- MGNX 2013
- Fundamental
- Price
- CSPI $16.26
- MGNX $2.27
- Analyst Decision
- CSPI
- MGNX Hold
- Analyst Count
- CSPI 0
- MGNX 10
- Target Price
- CSPI N/A
- MGNX $7.17
- AVG Volume (30 Days)
- CSPI 43.2K
- MGNX 650.0K
- Earning Date
- CSPI 02-10-2025
- MGNX 03-20-2025
- Dividend Yield
- CSPI 0.74%
- MGNX N/A
- EPS Growth
- CSPI N/A
- MGNX N/A
- EPS
- CSPI 0.02
- MGNX N/A
- Revenue
- CSPI $55,514,000.00
- MGNX $141,329,000.00
- Revenue This Year
- CSPI N/A
- MGNX $177.84
- Revenue Next Year
- CSPI N/A
- MGNX N/A
- P/E Ratio
- CSPI $868.41
- MGNX N/A
- Revenue Growth
- CSPI N/A
- MGNX 16.68
- 52 Week Low
- CSPI $10.76
- MGNX $2.15
- 52 Week High
- CSPI $24.44
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- CSPI 45.15
- MGNX 34.98
- Support Level
- CSPI $15.14
- MGNX $2.15
- Resistance Level
- CSPI $16.90
- MGNX $2.48
- Average True Range (ATR)
- CSPI 1.09
- MGNX 0.18
- MACD
- CSPI -0.23
- MGNX -0.01
- Stochastic Oscillator
- CSPI 23.38
- MGNX 15.00
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).